Physician profile
Charles Raine
NPI 1255393211
$3,635.43
in general payments reported to CMS, 2019-2025
15 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $2,154 · 2021: $49.57 · 2022: $69.17 · 2023: $179 · 2024: $45.86 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,232.65 | 2019-2023 | |
| Insulet Corporation | $540.08 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $284.69 | 2019-2024 | Mounjaro, Jardiance, Lyumjev |
| Corcept Therapeutics | $136.03 | 2019-2025 | Korlym |
| Mannkind Corporation | $118.99 | 2019-2020 | |
| Valeritas, INC. | $101.25 | 2019 | |
| Xeris Pharmaceuticals, INC. | $45.75 | 2021-2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.93 | 2019-2023 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $37.55 | 2019 | |
| Medtronic Minimed, INC. | $28.01 | 2019-2020 | |
| Esperion Therapeutics, INC. | $16.30 | 2020 | |
| Lifescan, INC. | $15.81 | 2019 | |
| Novo Nordisk INC | $13.73 | 2019 | |
| Pfizer INC. | $13.66 | 2025 | |
| Cequr Corporation | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Raine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.